Table 2.

Multivariate analysis assessing the 10-year mTSS progression and 10-year HAQ-DI: final models using SDAI as disease activity score

Outcome	Variables	Wald test	p-value
Ten-year mTSS progression	Centre	16.5	NS
	Baseline erosions	59.9	< 0.0001
	SDAI group	8.1	0.01
	SDAI group* time	4.5	NS
	SDAI*intercept	0.6	NS
	ACPA	0.4	NS
	ACPA*time	30.6	< 0.0001
	ACPA*intercept	7.3	0.006
	Time	1.5	NS
	Intercept	1.1	NS
Results of the contrast method	Final model:
	LDA versus remission	3.2	< 0.01
	MDA or HDA versus remission	4.5	< 0.0001
	MDA or HDA versus LDA	2.1	< 0.05
Ten-year HAQ-DI	RF	8.3	< 0.01
	bDMARD	11.9	< 0.001
	SDAI group	57.5	< 0.0001
	SDAI group*time	98.9	< 0.0001
	SDAI group*intercept	72.1	< 0.0001
	DMARDs use	0.04	NS
	DMARDs use*time	6.1	< 0.05
	DMARDs use*intercept	7.5	< 0.01
	Methotrexate use	0.1	NS
	Methotrexate*time	1.7	NS
	Corticosteroids use	3.9	< 0.05
	Corticosteroids use*time	6.7	<  < 0.01
	Corticosteroids use*intercept	5.8	< 0.05
	Time	12.7	< 0.001
	Intercept	9.5	< 0.01
Results of the contrast method	Final model:
	LDA versus remission	5.2	< 0.0001
	MDA or HDA versus remission	9.0	< 0.0001
	MDA or HDA versus LDA	5.6	< 0.0001

mTSS van der Heijde modified Total Sharp Score, SDAI Simple Disease Activity Index, ACPA anti-citrullinated peptide antibodies, DMARD disease-modifying anti-rheumatic drugs, bDMARDs biologic disease-modifying anti-rheumatic drugs. The included variables tested with univariate then multivariate analyses included: disease activity group based on SDAI, age, sex, smoking, duration of symptoms, centre of inclusion, presence of rheumatoid and/or ACPA factors, presence of erosion at diagnosis, synthetic background treatment, corticosteroids and bDMARD use